Glioma clinical trials in Massachusetts
20 studies for Glioma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Recruiting
All ages · All sexes · Updated Oct 1, 2026 · NCT06000787A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797CARv3-TEAM-E T Cells in Glioblastoma
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT05660369Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Dana-Farber Cancer Institute, Boston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Dana-Farber Cancer Institute, Boston
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
RecruitingPhase 1
12 Months – 18 Years · All sexes · Updated Mar 17, 2026 · NCT04943848CUE-102 in Recurrent Glioblastoma
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT06917885NeuroPathways Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Recruiting
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT05976490ASCENT Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Recruiting
Ages 18 and older · All sexes · Updated Jul 14, 2025 · NCT06099743The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 22, 2024 · NCT06118723From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.